BNP Paribas Asset Management’s Dianthus Therapeutics DNTH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$24.3K Buy
290
+74
+34% +$4.29K ﹤0.01% 1971
2025
Q4
$9K Buy
+216
New +$8.37K ﹤0.01% 2164

Other funds holding DNTH

BNP Paribas Asset Management's DNTH Position: Q1 2026 in Review

BNP Paribas Asset Management increased its Dianthus Therapeutics (DNTH) stake by 34% in Q1 2026, buying an estimated $4.29K and bringing the position to 290 shares worth $24.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1971.

BNP Paribas Asset Management first reported a position in DNTH in Q4 2025 and has held it in 2 quarters since. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • BNP Paribas Asset Management held 290 shares of Dianthus Therapeutics worth $24.3K as of Q1 2026.
  • BNP Paribas Asset Management bought 74 Dianthus Therapeutics shares in Q1 2026, an estimated $4.29K.
  • Dianthus Therapeutics made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q1 2026, its #1971 holding.
  • BNP Paribas Asset Management first reported a position in Dianthus Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on BNP Paribas Asset Management's 13F filing for Q1 2026, filed 14 May 2026.